Per Svenningsson's research group - our research
Translational Research on Neuropharmacology and Movement Disorders
We are a translational and multidisciplinary research group studying movement disorders, particularly Parkinson’s disease, and depression. We use cellular and animal models and analyze samples and biopsies from patients. Our goals are to understand the molecular mechanisms underlying disease states, and to identify novel biomarkers and medically relevant therapeutic targets.
At the clinic, we do longitudinal studies on cohorts of patients with Parkinson’s disease and other movement disorders, assessing both motor and non-motor symptoms. We also perform clinical trials with novel pharmacological therapies.
Our pre-clinical research lab is a multidisciplinary team, organized in 2 overarching research themes (click on each theme to read more on our lab webpage):
Our clinical research teams are organized into the following overarching research themes (click on each theme to read more on our lab webpage):
- Clinical trials and Biofluid Biomarkers in Parkinsonism
- Ataxia, spastic paraparesis, chorea and other movement disorders
- The role of glycemic control in Parkinson’s Disease
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
Markaki I, Ntetsika T, Sorjonen K, Svenningsson P,
Mov Disord 2021 Feb;():
TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition.
Mantas I, Vallianatou T, Yang Y, Shariatgorji M, Kalomoiri M, Fridjonsdottir E, Millan MJ, Zhang X, Andrén PE, Svenningsson P
Biol Psychiatry 2020 Dec;():
P11 deficiency increases stress reactivity along with HPA axis and autonomic hyperresponsiveness.
Sousa VC, Mantas I, Stroth N, Hager T, Pereira M, Jiang H, Jabre S, Paslawski W, Stiedl O, Svenningsson P
Mol Psychiatry 2020 Oct;():
A Novel Duplication in ATXN2 as Modifier for Spinocerebellar Ataxia 3 (SCA3) and C9ORF72-ALS.
Laffita-Mesa JM, Nennesmo I, Paucar M, Svenningsson P
Mov Disord 2021 Feb;36(2):508-514
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J,
Mov Disord 2020 06;35(6):1046-1054
α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.
Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P
Proc Natl Acad Sci U S A 2019 07;116(30):15226-15235
Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease.
Green H, Zhang X, Tiklova K, Volakakis N, Brodin L, Berg L, Greengard P, Perlmann T, Svenningsson P
Proc Natl Acad Sci U S A 2017 03;114(10):2735-2740
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H
Brain 2015 Apr;138(Pt 4):963-73
Alterations in 5-HT1B receptor function by p11 in depression-like states.
Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P
Science 2006 Jan;311(5757):77-80
Full list of publications:
Join our team
Ad-hoc applications are welcome. Please email research group leader Per Svenningsson at: email@example.com
Our research has been supported by grants from the following institutions and funding agencies: